Laboratory of Applied Pharmacokinetics and Bioinformatics
Optimizing drug therapy for populations and individuals

LAPK Written Tutorials

    Introduction and Review of Basic pharmacokinetics, related responses, and Clinical Applications

  1. New Optical Illusions

    Ref.:
    1. Related Slides (.pdf)

  2. Review of Basic Pharmacokinetics

    Ref.:
    1. Introduction to basic pharmacokinetics, and individualization of drug therapy (.pdf)
    2. Goal-oriented, model-based drug regimens: Setting individualized
      goals for each patient       (.pdf)

  3. Evaluating Renal Function

    Ref.:
    1. Estimation of creatinine clearance in patients with unstable renal function,
      without a urine specimen.       (.pdf)
    2. Related slides (.pdf)

  4. Bayes' Theorem and the MAP Bayesian Scenario of Planning,
    Monitoring, and Adjusting drug dosage for patients

    Ref.:
    1. Achieving concentration goals using parametric pharmacokinetic models -
      a clinical review of the current unimodal gaussian bayesian approach       (.pdf)
    2. Bayes' Theorem (.pdf)
    3. New types of Bayesian Parameter Updating (.pdf)

  5. Modeling diffusion into endocardial vegetations, and the
    postantibiotic effect

    Ref.:
    1. Linked pharmacodynamic models: Diffusion into endocardial vegetations,
      postantibiotic effect, and bacterial growth and kill       (.pdf)
    2. Related slides (.pdf)

  6. Modeling bacterial growth and kill

  7. Demo Vancomycin - Setting the initial goals. Planning the initial
    regimen. - Dr. Paul Beringer

    Ref.:
    1. Clinical Applications: Vancomycin (.pdf)

  8. Introduction to Population Modelling
    Why model? For description? For action? For what purpose?
    Linear regression, Weighted Nonlinear Least Squares

    Optimal procedures for population modelling
    First, determine the assay error pattern, to weight each data point properly
    Second, use a parametric population model, get gamma, ranges
    Third, use an NP population model, use gamma, ranges, get
    the entire parameter distribution. Why?

    Ref.:
    1. Population pharmacokinetic models: Parametric and nonparametric approaches (.pdf)
    2. Related slides (.pdf)

  9. Optimal Strategies for PK/PD Studies and for Patient Monitoring

    Ref.:
    1. Related slides (.pdf)

  10. Multiple Model Dosage Design for maximally precise goal oriented,
    model based drug dosage regimens

    Ref.:
    1. Multiple Model (mm) Dosage design: Achieving target goals with maximum precision (.pdf)
    2. Related slides (.pdf)
    3. Interacting Multiple Model Sequential Bayesian posterior joint parameter densities
      to detect changing parameter values during the period of data analysis       (.pdf)

  11. Maximum Entropy Methods for Creating Discrete Joint Densities for
    Multiple Model Dosage Design - Dr. Mark Milman

    Ref.:
    1. Related slides (.pdf)

    Intermediate and Advanced Population Modeling


  12. Development of a Pharmacokinetic Model of Ciprofloxacin
    in Adult CF Patients - Dr. Paul Beringer

    Ref.:
    1. PK/PD of Ciprofloxacin in Patients with Cystic Fibrosis (.pdf)

  13. Determining the Assay Error Pattern: the First Step in Population
    Modeling and TDM

    Ref.:
    1. Fitting drug concentration data according to its credibility:
      Determining the assay error pattern       (.pdf)
    2. Related slides (.pdf)

  14. Bioavailability Studies

    Ref.:
    1. Related slides (.pdf)

  15. Population PK/PD modeling

    Ref.:
    1. POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING (.pdf)
    2. New advances in nonparametric pk/pd population modeling (.pdf)
    3. Adaptive grid NP models (.pdf)
    4. Population PK/PD modeling on the web (.pdf)
    5. A unified parametric/nonparametric approach to population PK/PD modeling (.pdf)
    6. Comparative Performance in analysing a clinical data set and two monte carlo simulation studies (.pdf)

  16. Optimal Drug dosage

    Ref.:
    1. Multiple model dosage design (.pdf)

  17. Clinical Applications

    Ref.:
    1. OPTIMIZING INDIVIDUALIZED DOSAGE REGIMENS OF POTENTIALLY TOXIC DRUGS (.pdf)
    2. Reduced transplant mortality (.pdf)
    3. A hemodynamic database (.pdf)
    4. Stochastic analysis (.pdf)

  18. Parametric and Nonparametric Population Methods (Preprint in Clinical Pharmacokinetics, 45:365-383, 2006)

    Ref.:
    1. Their Comparative Performance in Analysing a Clinical Data Set and Two Monte Carlo Simulation Studies (.pdf)